Figure 4From: Quality of asthma care under different primary care models in Canada: a population-based studyShort-acting β2-agonist use. a. Short-acting β2-agonist use in the past 12 months for asthma patients >65 years of age. b. Short-acting β2-agonist use ≤4 canisters in the past 12 months for asthma patients >65 years of age. c. Short-acting β2-agonist use ≥13 canisters in the past 12 months for asthma patients >65 years of ageBack to article page